DDInter1843 DDInter1840
Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Trandolapril {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metformin
Metformin {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Trandolapril {u} (Compound) treats {v} (Disease) hypertension
hypertension {u} (Disease) is associated with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metformin
Metformin {u} (Compound) causes {v} (Side Effect) Oedema peripheral
Oedema peripheral {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flurbiprofen
Flurbiprofen {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dronabinol
Dronabinol {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flurbiprofen
Flurbiprofen {u} (Compound) causes {v} (Side Effect) Pulmonary embolism
Pulmonary embolism {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Trandolapril {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Nateglinide {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Trandolapril {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Nateglinide {u} (Compound) causes {v} (Side Effect) Oedema peripheral
Oedema peripheral {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Trandolapril {u} (Compound) resembles {v} (Compound) Enalapril
Enalapril {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Trandolapril (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Trandolapril (Compound) treats hypertension (Disease) and hypertension (Disease) is associated with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin (Compound) causes Oedema peripheral (Side Effect) and Oedema peripheral (Side Effect) is caused by Trabectedin (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Trabectedin (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Trabectedin (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen (Compound) causes Pulmonary embolism (Side Effect) and Pulmonary embolism (Side Effect) is caused by Trabectedin (Compound)
Trandolapril (Compound) resembles Nateglinide (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Trabectedin (Compound)
Trandolapril (Compound) resembles Nateglinide (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide (Compound) causes Oedema peripheral (Side Effect) and Oedema peripheral (Side Effect) is caused by Trabectedin (Compound)
Trandolapril (Compound) resembles Enalapril (Compound) and Enalapril (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)